2,5-Dihydroxyacetophenone attenuates RANKL-mediated osteoclastogenesis by affecting the NFATc1 signaling pathway in...

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Osteoclast overactivity drives bone loss in conditions like osteoporosis.
• Natural compounds offer potential therapeutic strategies for osteolytic diseases.
• Ganoderma bambusicola contains phenolic compounds with potential bioactivity.

Purpose of the Study:

• To investigate the anti-osteoclastogenic effects of 2,5-dihydroxyacetophenone (DHAP).
• To elucidate the molecular mechanisms by which DHAP affects osteoclast differentiation and function.
• To assess DHAP's impact on RANKL-induced osteoclastogenesis in vitro.

Main Methods:

• In vitro osteoclast differentiation models using RANKL stimulation.
• Assessment of osteoclast differentiation markers (actin ring formation, TRAP activity).
• Analysis of gene and protein expression (NFATc1, Cathepsin K, TRAP).
• Evaluation of bone resorption activity.
• Investigation of signaling pathways (NFATc1, AP-1, NF-κB, ROS).

Main Results:

• DHAP significantly inhibited osteoclast differentiation, actin ring formation, and bone resorption.
• DHAP suppressed the transcriptional activity of NFATc1 during osteoclastogenesis.
• Reduced expression of NFATc1, Cathepsin K (Ctsk), and TRAP was observed.
• DHAP did not affect reactive oxygen species (ROS) production or AP-1 and NF-κB signaling.

Conclusions:

• DHAP exhibits potent anti-osteoclastogenic activity by inhibiting RANKL-induced osteoclast differentiation and function.
• The primary mechanism involves the suppression of the NFATc1 signaling pathway.
• DHAP represents a potential therapeutic candidate for managing osteolytic bone diseases.